Hyun Joon Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hyun Joon Park has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Kwang Il Seo
Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea
4 shared publications - Jung Wook Lee
Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
2 shared publications - Sang Uk Lee
Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
2 shared publications - Bang Ju Kim
Department of Internal Medicine, Jecheon Myongji Hospital, Jecheon, Korea
1 shared publication - Byung Cheol Yun
Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
1 shared publication - Gyoo-Sik Jung
Department of Radiology, Ulsan Medical Center, 13, 171 bun-gil, Wolpyoung-ro, Nam-gu, Ulsan 44686, South Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (17) , e134
Nutritional Risk Assessed by Royal Free Hospital-Nutritional Prioritizing Tool Predicts Survival in Cirrhosis With or Without Hepatocellular Carcinoma
Park HJ, et al. J Korean Med Sci. 2026 May;41:e134. https://doi.org/10.3346/jkms.2026.41.e134
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (17) , e134
Open AccessNutritional Risk Assessed by Royal Free Hospital-Nutritional Prioritizing Tool Predicts Survival in Cirrhosis With or Without Hepatocellular Carcinoma
Park HJ, et al. J Korean Med Sci. 2026 May;41:e134. https://doi.org/10.3346/jkms.2026.41.e134
- Open Access
- 30 June 2025
- Published by Kosin University College of Medicine in Kosin Medical Journal
- Vol. 40 (2) , 150-156
Brain hemorrhage in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
A combination of atezolizumab and bevacizumab is currently recommended for treating unresectable advanced-stage hepatocellular carcinoma (HCC), as it has demonstrated superior overall survival and progression-free survival compared to sorafenib. However, concerns have been raised regarding serious adverse events associated with bevacizumab, such as gastrointestinal perforation, fistula, hemorrhage, and arterial thromboembolism. In particular, patients with liver cirrhosis (LC) show an increased risk of variceal bleeding. However, brain hemorrhage associated with the use of bevacizumab in patients with HCC and LC is extremely rare. We encountered two cases of brain hemorrhage in patients with HCC and LC who underwent treatment with atezolizumab and bevacizumab. One patient had no history of hypertension, while the other patient had hypertension that was well-controlled with medication and an unruptured brain aneurysm located on the right side of the anterior communicating artery. Both patients experienced brain hemorrhage after two treatment cycles of atezolizumab with bevacizumab. One patient died due to brain hemorrhage, while the other patient recovered from subarachnoid hemorrhage with successful coil embolization. This case report suggests that if a patient has any high-risk factors associated with brain hemorrhage, physicians should thoroughly consider alternative treatment options for advanced HCC, as brain hemorrhage could be fatal.
- 30 June 2025
- Published by Kosin University College of Medicine in Kosin Medical Journal
- Vol. 40 (2) , 150-156
Open AccessBrain hemorrhage in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
A combination of atezolizumab and bevacizumab is currently recommended for treating unresectable advanced-stage hepatocellular carcinoma (HCC), as it has demonstrated superior overall survival and progression-free survival compared to sorafenib. However, concerns have been raised regarding serious adverse events associated with bevacizumab, such as gastrointestinal perforation, fistula, hemorrhage, and arterial thromboembolism. In particular, patients with liver cirrhosis (LC) show an increased risk of variceal bleeding. However, brain hemorrhage associated with the use of bevacizumab in patients with HCC and LC is extremely rare. We encountered two cases of brain hemorrhage in patients with HCC and LC who underwent treatment with atezolizumab and bevacizumab. One patient had no history of hypertension, while the other patient had hypertension that was well-controlled with medication and an unruptured brain aneurysm located on the right side of the anterior communicating artery. Both patients experienced brain hemorrhage after two treatment cycles of atezolizumab with bevacizumab. One patient died due to brain hemorrhage, while the other patient recovered from subarachnoid hemorrhage with successful coil embolization. This case report suggests that if a patient has any high-risk factors associated with brain hemorrhage, physicians should thoroughly consider alternative treatment options for advanced HCC, as brain hemorrhage could be fatal.
- Open Access
- 30 June 2023
- Published by Kosin University College of Medicine in Kosin Medical Journal
- Vol. 38 (2) , 75-86
Polycystic liver disease: an overview of clinical manifestations, diagnosis, and treatment
Polycystic liver disease (PLD) is a hereditary disease characterized by the presence of 20 or more liver cysts. It is classified into three types: isolated autosomal dominant PLD, PLD with autosomal dominant polycystic kidney disease, and PLD with autosomal recessive polycystic kidney disease. Genetic alterations, ciliary dysfunction of the biliary epithelial cells, and aberrant cell signaling pathways are the main factors contributing to the pathophysiology of PLD; however, other complicated mechanisms are also involved. The Gigot and Schnelldorfer classifications are widely used in clinical practice. Most patients with PLD are asymptomatic; however, a few patients with advanced-stage disease may develop symptoms and complications that impair their quality of life and require treatment. The known treatment options for PLD are somatostatin analogues, aspiration with sclerotherapy, fenestration, hepatic resection, and liver transplantation. Although liver transplantation remains the only curative treatment for PLD, medical therapies are gradually being developed with the increasing knowledge of the disease’s pathophysiology. This review focuses on the clinical manifestations and diagnosis of PLD, as well as treatment strategies, to support clinicians regarding the clinical management of the disease.
- 30 June 2023
- Published by Kosin University College of Medicine in Kosin Medical Journal
- Vol. 38 (2) , 75-86
Open AccessPolycystic liver disease: an overview of clinical manifestations, diagnosis, and treatment
Polycystic liver disease (PLD) is a hereditary disease characterized by the presence of 20 or more liver cysts. It is classified into three types: isolated autosomal dominant PLD, PLD with autosomal dominant polycystic kidney disease, and PLD with autosomal recessive polycystic kidney disease. Genetic alterations, ciliary dysfunction of the biliary epithelial cells, and aberrant cell signaling pathways are the main factors contributing to the pathophysiology of PLD; however, other complicated mechanisms are also involved. The Gigot and Schnelldorfer classifications are widely used in clinical practice. Most patients with PLD are asymptomatic; however, a few patients with advanced-stage disease may develop symptoms and complications that impair their quality of life and require treatment. The known treatment options for PLD are somatostatin analogues, aspiration with sclerotherapy, fenestration, hepatic resection, and liver transplantation. Although liver transplantation remains the only curative treatment for PLD, medical therapies are gradually being developed with the increasing knowledge of the disease’s pathophysiology. This review focuses on the clinical manifestations and diagnosis of PLD, as well as treatment strategies, to support clinicians regarding the clinical management of the disease.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of the Korean Society of Radiology
- Vol. 84 (6) , 1350-1360
Predictive Factors for Symptomatic Dislodgement of Percutaneous Transhepatic Biliary Drainage Catheter in Patients with Malignant Biliary Obstruction
유희정, et al. J Korean Soc Radiol. 2023 Oct;84:e113. /Synapse/10.3348/jksr.2023.0063
- 1 January 2023
- Published by XMLink in Journal of the Korean Society of Radiology
- Vol. 84 (6) , 1350-1360
Open AccessPredictive Factors for Symptomatic Dislodgement of Percutaneous Transhepatic Biliary Drainage Catheter in Patients with Malignant Biliary Obstruction
유희정, et al. J Korean Soc Radiol. 2023 Oct;84:e113. /Synapse/10.3348/jksr.2023.0063
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (30) , e193
Association between Parental Cotinine-verified Smoking Status and Childhood Asthma: a Population-based Nationally Representative Analysis
Jung J, et al. J Korean Med Sci. 2021 Jun;36(30):e193. https://doi.org/10.3346/jkms.2021.36.e193
- 1 January 2021
- Published by XMLink in Journal of Korean Medical Science
- Vol. 36 (30) , e193
Open AccessAssociation between Parental Cotinine-verified Smoking Status and Childhood Asthma: a Population-based Nationally Representative Analysis
Jung J, et al. J Korean Med Sci. 2021 Jun;36(30):e193. https://doi.org/10.3346/jkms.2021.36.e193
- Open Access
- 31 December 2020
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 34 (4) , 279-285
Liver transplantation for azithromycin-induced severe liver injury
Hyun Joon Park, Kwang Il Seo, Young Il Choi. Korean J Transplant 1999;0:. https://doi.org/10.4285/kjt.20.0017
- 31 December 2020
- Published by The Korean Society for Transplantation in Korean Journal of Transplantation
- Vol. 34 (4) , 279-285
Open AccessLiver transplantation for azithromycin-induced severe liver injury
Hyun Joon Park, Kwang Il Seo, Young Il Choi. Korean J Transplant 1999;0:. https://doi.org/10.4285/kjt.20.0017